Book Navigation
 

International guideline library update

New Publications published in the International Guideline Library – 25th June to 17th September 2012

Organisation

AHRQ (US)

(1) U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th edition. (2) Update to CDC's U.S. medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. (3) Update to CDC's U.S. medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. Centers for Disease Control and Prevention. NGC:009194

AHRQ (US)

Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. Collaborative Group of the Americas on Inherited Colorectal Cancer. National Society of Genetic Counselors. NGC:009003

AHRQ (US)

Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. U.S. Preventive Services Task Force. NGC:009010

AHRQ (US)

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. United States Preventive Services Task Force. NGC:009101

AHRQ (US)

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. American Association for the Study of Liver Diseases. American College of Gastroenterology. American Gastroenterological Association Institute.NGC:009150

AHRQ (US)

The role of endoscopy in the management of acute non-variceal upper GI bleeding. American Society for Gastrointestinal Endoscopy. NGC:009182

AHRQ (US)

UK national guidelines on the management of adult and adolescent complainants of sexual assault 2011. British Association for Sexual Health and HIV. NGC:008972

ASCO (US)

Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline

AWMF (DE)

Chronische Pankreatitis. S3-LL (DGVS, DGCH, DGE)
[Chronic pancreatitis]

AWMF (DE)

Diagnostik und Therapie von Harnstoffzyklusstörungen. S3-LL (DGKJ, APS)
[Diagnosis and treatment of urea cycle disorders]

AWMF (DE)

Diagnostik und Therapie des Karpaltunnelsyndroms. S3-LL (DGH/DGNC/DGN/DGOOC)
[Diagnosis and management of carpal tunnel syndrome]

AWMF (DE)

Extracranielle Carotisstenose; Diagnostik, Therapie und Nachsorge. S3-LL (DGG, DDG, DGA)
[Extracranial carotid stenosis; Diagnosis, treatment and aftercare]

AWMF (DE)

Lokaltherapie chronischer Wunden bei Patienten mit den Risiken periphere arterielle Verschlusskrankheit, Diabetes Mellitus, chronisch venöse Insuffizienz. S3-LL (DGfW, DDG, DDG)
[Management of chronic wounds in patients with the risk of arterial occlusive disease, diabetes mellitus, chronic venous insufficiency]

AWMF (DE)

Zerebrale Anfälle beim Neugeborenen. S2k-LL (GNPI, DGKJ, GNP)
[Cerebral seizures in newborns]

DKG (DE)

Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau (Leitlinienprogramm Onkologie von AWMF, DKG und DKH)
[Interdisciplinary S3 Guidelines for Diagnosis, Treatment and Follow-up Care of Breast Cancer]

IKNL (NL)

Melanoom
[Skin melanoma]

IKNL (NL)

Spiritual care (english summary)
[Spiritual care]

IQWiG (DE)

Ipilimumab - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Belimumab - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Belimumab - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)]

IQWiG (DE)

Fampridin - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Fampridine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Addendum zum Auftrag A12-02 (Rilpivirin/Emtricitabin/Tenofovir)
[Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Nutzenbewertung einer langfristigen Blutdrucksenkung in den unteren normotonen Bereich bei Patienten mit Diabetes mellitus
[Benefit assessment of long-term lowering of blood pressure to levels in the lower normal range in patients with diabetes mellitus - Rapid report]

IQWiG (DE)

Tiotropiumbromid bei COPD
[Tiotropium bromide in the treatment of chronic obstructive pulmonary disease]

IQWiG (DE)

Vandetanib - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Vandetanib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

IQWiG (DE)

Vemurafenib - Nutzenbewertung gemäß § 35a SGB V (Dossierbewertung)
[Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]

MoH (UA)

Ведення диспепсії у дорослих. Адаптована клінічна настанова, заснована на доказах
[Management of dyspepsia in adults. Adapted evidence-based guideline]

MoH (UA)

Сучасні принципи діагностики та лікування хворих із гострим ішемічним інсультом та ТІА. Адаптована клінічна настанова, заснована на доказах
[Modern principles of diagnosis and management of patients with acute ischemic stroke and TIA. Adapted evidence-based guideline]

MoH (UA)

Первинна медична допомога при припиненні вживання тютюнових виробів. Адаптована клінічна настанова, заснована на доказах
[Primary medical care in smoking cessation. Adapted evidence-based guideline]

MoH (UA)

Рекомендації щодо ведення хворих з ішемічним інсультом та транзиторною ішемічною атакою. Адаптована клінічна настанова, заснована на доказах
[Recommendations for the management of patients with ischemic stroke and transient ischemic attack. Adapted evidence-based guideline]

NICE (GB)

Autism in adults (CG142)

NICE (GB)

Lower limb peripheral arterial disease (CG147)

NICE (GB)

Preventing type 2 diabetes - risk identification and interventions for individuals at high risk (PH38)

NICE (GB)

Sickle cell acute painful episode (CG143)

NICE (GB)

Spasticity in children and young people (CG145)

NICE (GB)

Venous thromboembolic diseases (CG144)

SIGN (GB)

Management of suspected bacterial urinary tract infection in adults (SIGN CPG 88)

 
enGINe Newsletter

Subscribe here to the enGINe Newsletter.


Page last updated: Oct 20, 2012
Copyright © 2002-2016 Guidelines International Network.
All rights reserved

The Guidelines International Network is formally constituted as a Scottish Guarantee Company under Company Number SC243691 and recognised as a Scottish Charity under Scottish Charity Number SC034047 with its Registered Office at J. & H. Mitchell W.S., 51 Atholl Road, Pitlochry, Perthshire PH16 5BU, Scotland.

Back to top